This Article Full Text Full Text (PDF) All Versions of this Article: 40/2/e24    most recent STROKEAHA.108.540062v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Grond-Ginsbach, C. Articles by Reuner, K. Search for Related Content PubMed PubMed Citation Articles by Grond-Ginsbach, C. Articles by Reuner, K.

(Stroke. 2009;40:e24.)
© 2009 American Heart Association, Inc.

Letters to the Editor

No Association of the Plasma Glutathione Peroxidase (GPx-3) Gene With Cerebral Venous Thrombosis in the German Population

Deparment of Neurology, University of Heidelberg, Heidelberg, Germany

Armin Grau, MD

Department of Neurology, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany

Karl Reuner, MD

Institut für Labormedizin, Kassel, Germany

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

In a recent publication in Stroke, cerebral venous thrombosis (CVT) was found to be associated with a variant of the plasma glutathione peroxidase (GPx-3) gene (promoter haplotype H₂).¹ The observed association was strong (OR >10) and highly significant (P<0.0001). However, the number of analyzed patients was small (n=23) and the findings were not confirmed in an independent study population. We analyzed 79 patients with nonseptic CVT and 203 healthy control subjects and sought to confirm the association between GPx-3 and CVT. Our study groups were characterized in detail elsewhere.² We tagged haplotype H₂ with SNP rs1946235 (this is polymorphism –927 T/C in the study of Voetsch et al¹) as described before.³ The C allele of rs1946235 identifies haplotype H₂, as well as the rare (<1% in our population) haplotypes H₇ and H₈.

In our series of healthy control subjects, we found 3 homozygous and 52 heterozygous carriers of haplotype H₂. The frequency of H₂ in this control series is therefore 14.3%. In the patients group we found one homozygous and 17 heterozygous carriers of haplotype H₂ (estimated frequency of H₂=12.0%). Comparison of the H₂ frequencies in the 2 study groups by ² testing revealed that the difference was not significant (P=0.48).

In an additional series of 500 healthy German control persons, we genotyped SNP rs1946235 and found 11 CC, 112 CT and 377 TT, which corresponds to an estimated H₂ frequency of 13.4%.

Our findings . . . [Full Text of this Article]